The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Pfizer ($PFE) became a household name during the pandemic, and its stock rose along with its fame. However, three years later ...

Roche's diversified portfolio and ongoing GLP-1 developments offer decent upside with limited downside. Read more about RHHBY ...

Phase I data for TERN-601 suggests Terns’ oral GLP-1 candidate for obesity could be a contender in the market next to big ...

The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...

Market leaders Wegovy from Novo Nordisk and Zepbound from Eli Lilly are both injectable drugs. The two companies are also ...

This big drugmaker's current challenges present an excellent buying opportunity for forward-thinking investors.

In this article, we take a look at six biotech companies focused on bringing drugs to treat obesity to the market.

Founded in 2008 with only three people in a small laboratory in Milton Park in Oxfordshire, England, Adaptimmune has since expanded into a globally recognized biotech company. Now, with hundreds of ...

Pfizer currently trails its competitors after disappointing trial results for its twice-daily drug danuglipron, which raised concerns about potential liver damage. The company is shifting its ...